Keywords: pfizer/avant, candidate, may, increase, survival, rate, gbm

Pfizer/Avant candidate may increase survival rate in GBM patients

Article | 16 June 2008

Print This

USA-based Avant and global drug giant Pfizer released new data from two Phase II studies for CDX-110, an investigational immunotherapeutic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in